Physician profile
Khalid Arshad
NPI 1306259817
$7,882.76
in general payments reported to CMS, 2019-2025
30 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $123 · 2021: $583 · 2022: $1,537 · 2023: $1,775 · 2024: $1,996 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,354 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,353.83 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,267.04 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $674.26 | 2022-2025 | Ingrezza |
| Indivior INC. | $571.65 | 2020-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $555.30 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $551.28 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $541.84 | 2021-2025 | Caplyta |
| Alkermes, INC. | $477.62 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $379.20 | 2022-2024 | Vraylar |
| Ironshore Pharmaceuticals INC. | $376.38 | 2019-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $337.44 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $289.30 | 2023-2025 | Auvelity |
| Corium, LLC | $272.82 | 2021-2024 | Azstarys |
| Lundbeck LLC | $264.01 | 2019-2024 | Rexulti |
| Tris Pharma INC | $258.97 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Almatica Pharma LLC | $241.87 | 2021-2024 | Loreev Xr, Sertraline Hcl |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $213.90 | 2020-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $89.68 | 2022-2025 | Fanapt, Hetlioz |
| Biogen, INC. | $71.85 | 2024-2025 | Zurzuvae |
| Sunovion Pharmaceuticals INC. | $63.99 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $57.68 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $54.59 | 2022-2023 | Belsomra |
| Neos Therapeutics, Lp | $54.43 | 2019-2020 | |
| Shire North American Group INC | $53.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $51.26 | 2024-2025 | Cobenfy |
| Luye Pharma (USA) Ltd. | $45.59 | 2025 | Erzofri Extended-Release |
| Collegium Pharmaceutical, INC. | $15.32 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $13.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.68 | 2019 | |
| Acadia Pharmaceuticals INC | $12.12 | 2021 | |
| Eisai INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.